ArticleArchives of medical science : AMS2023
Novel green synthesis of silver nanoparticles mediated by
Article in Archives of medical science : AMS, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Unlocking the Therapeutic Efficacies of Silver Nanoparticles Derived Using the Plant-Based Aqueous Extract: A Comprehensive Review.Applied biochemistry and biotechnology · 2026Review
- Green Metallic Nanoparticles for Cancer Therapy: Evaluation Models and Cancer Applications.Pharmaceutics · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: The present work describes the green synthesis and characterization and cytotoxicity, antioxidant, and anti-human lung cancer activities of silver nanoparticles containing Material and methods: Ag nanoparticles were produced by mixing the AgNO Results: They had very low cell viability and high anti-human lung cancer activities dose-dependently against HLC-1, LC-2/ad, and PC-14 cell lines without any cytotoxicity towards the normal cell line (HUVEC). The IC50 values of Ag nanoparticles were 249, 187, and 152 μg/ml against HLC-1, LC-2/ad, and PC-14 cell lines, respectively. The best results of cytotoxicity and anti-human lung cancer properties were seen at the concentration of 1000 μg/ml. Ag nanoparticles inhibited half of the DPPH molecules in the concentration of 135 μg/ml. Maybe significant anti-human lung cancer potentials of Ag nanoparticles synthesized by Conclusions: After confirming the above results in the clinical trial research, this formulation can be administered to treat human lung cancers in humans.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.